Welcome to the third of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions involving digital assets are an increasing focus for pharmaceuticals, medical device and medtech companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
In this third episode, we consider the challenges associated with defining and valuing digital assets. Aligning the target’s and acquiror’s views on valuation is obviously key to getting a deal done. Digital assets present some unique challenges for pharmaceutical companies more used to valuing molecules in traditional licensing or acquisition transactions. What techniques do they need to deploy to overcome this hurdle? Click below to listen. You can add the podcast series to one of several apps, such as Apple Podcasts, by clicking the "+ Follow" link.
If you want to listen to the first two episodes, please visit our Insights page. You can also learn more by downloading our report which accompanies this podcast series. 👇
Are you ready for a digital-first future in life sciences? This new report explores the challenges and opportunities presented by digital deals. Essential reading for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving artificial intelligence, machine learning and big data, our report provides insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. To receive a copy, please click here to fill in your details in the form at the bottom of the page. 👇
